drugset / Trial / NCT00635726
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
Phase 2
Terminated
41 enrolled
Hellenic Oncology Research Group
University Hospital of Crete · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial will study the effectiveness and toxicity of sequential high dose MVAC followed by gemcitabine and cisplatin, as first line treatment in patients with locally advanced or metastatic bladder cancer.
Timeline
- Start
- 2008-02
- Primary completion
- 2013-02
- Completion
- 2013-02
Outcome
Outcome not reported
Stopped (Enrollment): “Due to poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 70 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 30 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Methotrexate | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Vinblastine | Small molecule | 3 mg/m2 | — |